首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Development and evaluation of gastroretentive raft forming systems incorporating curcumin-Eudragit (R) EPO solid dispersions for gastric ulcer treatment
【24h】

Development and evaluation of gastroretentive raft forming systems incorporating curcumin-Eudragit (R) EPO solid dispersions for gastric ulcer treatment

机译:结合姜黄素-Eudragit(R)EPO固体分散体的胃滞留性筏形成系统的开发和评估,用于治疗胃溃疡

获取原文
获取原文并翻译 | 示例
       

摘要

Novel raft forming systems incorporating curcumin-Eudragit (R) EPO solid dispersions were developed to prolong the gastric residence time and provide for a controlled release therapy of curcumin to treat gastric ulcers. The solid dispersions of curcumin with Eudragit (R) EPO were prepared by the solvent evaporation method at various ratios to improve the solubility and the dissolution of curcumin. The optimum weight ratio of 1:5 for curcumin to Eudragit (R) EPO was used to incorporate into the raft forming systems. The raft forming formulations were composed of curcumin-Eudragit (R) EPO solid dispersions, sodium alginate as a gelling polymer and calcium carbonate for generating divalent Ca2+ ions and carbon dioxide to form a floating raft. All formulations formed a gelled raft in 1 min and sustained buoyancy on the 0.1 N hydrochloric acid (pH 1.2) surface with a 60-85% release of curcumin within 8 h. The curative effect on the acetic acid-induced chronic gastric ulcer in rats was determined. The curcumin raft forming formulations at 40 mg/kg once daily showed a superior curative effect on the gastric ulcer in terms of the ulcer index and healing index than the standard antisecretory agent: lansoprazole (1 mg/kg, twice daily) and a curcumin suspension (40 mg/kg, twice daily). These studies demonstrated that the new raft forming systems containing curcumin solid dispersions are promising carriers for a stomach-specific delivery of poorly soluble lipophilic compounds. (C) 2015 Elsevier B.V. All rights reserved.
机译:开发了结合姜黄素-Eudragit(R)EPO固体分散体的新型筏成型系统,以延长胃的停留时间并提供姜黄素的控释疗法以治疗胃溃疡。通过溶剂蒸发法以各种比例制备姜黄素与Eudragit EPO的固体分散体,以改善姜黄素的溶解度和溶解度。姜黄素与Eudragit(R)EPO的最佳重量比为1:5,可用于筏成型系统。筏形成制剂由姜黄素-Eudragit(R)EPO固体分散体,作为胶凝聚合物的海藻酸钠和用于生成二价Ca2 +离子的碳酸钙和二氧化碳组成,以形成漂浮筏。所有制剂均在1分钟内形成凝胶筏,并在0.1 N盐酸(pH 1.2)表面持续浮力,姜黄素在8小时内释放60-85%。确定了对乙酸诱导的大鼠慢性胃溃疡的治疗作用。每天一次40 mg / kg的姜黄素筏形成制剂在溃疡指数和愈合指数方面显示优于标准抗分泌剂兰索拉唑(1 mg / kg,每天两次)和姜黄素悬浮液对胃溃疡的治疗效果(40 mg / kg,每天两次)。这些研究表明,含有姜黄素固体分散体的新型筏形成系统是有希望的载体,可用于胃特异性递送难溶性亲脂性化合物。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号